Biomarkers predictive of response to pembrolizumab in head and neck cancer
David G. Pfister(Memorial Sloan Kettering Cancer Center), Joshua Bauml(University of Pennsylvania), Tanguy Y. Seiwert(Georgetown University), Ammar Sukari(The Barbara Ann Karmanos Cancer Institute), Francis P. Worden(Georgetown University), Lori J. Wirth(Massachusetts General Hospital), Erminia Massarelli(The University of Texas MD Anderson Cancer Center), Nabil F. Saba(Emory University), Andrea L. Webber(Merck & Co., Inc., Rahway, NJ, USA (United States)), Stephen V. Liu(Georgetown University), Ranee Mehra(University of Maryland, Baltimore), Lingkang Huang(Merck & Co., Inc., Rahway, NJ, USA (United States)), Jared Lunceford(Merck & Co., Inc., Rahway, NJ, USA (United States)), Răzvan Cristescu(Merck & Co., Inc., Rahway, NJ, USA (United States)), Laura Q.M. Chow(The University of Texas at Austin), Andrew Albright(Merck & Co., Inc., Rahway, NJ, USA (United States)), Hyunseok Kang(Johns Hopkins University), Robin Mogg(Merck & Co., Inc., Rahway, NJ, USA (United States)), Robert I. Haddad(Georgetown University), Jared Weiss(Georgetown University), Jonathan D. Cheng(Princeton University), Mark Ayers(Merck & Co., Inc., Rahway, NJ, USA (United States))
Cited by 48
Related Papers
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
|New England Journal of Medicine|2012|8k
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k
IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade
|Journal of Clinical Investigation|2017|3.9k
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.5k